Pildoras de 21 vs 28

Solo disponible en BuenasTareas
  • Páginas : 27 (6645 palabras )
  • Descarga(s) : 0
  • Publicado : 5 de diciembre de 2010
Leer documento completo
Vista previa del texto
Eur J Contracept Reprod Health Care. 1999 Nov;4 Suppl 2:17-25. |Related Articles, Compound via MeSH, Substance via MeSH, Cited in PMC, Books, LinkOut | |
Cycle control, safety and efficacy of a 24-day regimen of gestodene 60 microg/ ethinylestradiol 15 microg and a 21-day regimen of desogestrel 150 microg/ethinylestradiol 20 microg.

[No authors listed]

OBJECTIVE: Thismulticenter, open-label study was conducted to compare the cycle control, efficacy and safety of a 24-day regimen of a new ultra-low-dose oral contraceptive containing gestodene (GTD) 60 microg/ethinylestradiol (EE) 15 microg and a 21-day regimen of desogestrel (DSG) 150 microg/EE 20 microg. METHODS: Healthy women at least 18 years of age who had had regular menstrual cycles for the prior 3 monthswere randomly assigned to treatment for six cycles. RESULTS: Data from 1074 women were included in the analyses. Overall, 65% of cycles were normal with GTD/EE and 78% with DSG/EE. The overall incidence of breakthrough bleeding and/or spotting was 29% with GTD/EE and 20% with DSG/EE, with absence of bleeding occurring in 6% of cycles in the GTD/EE group and 1% of cycles in the DSG/EE group. TheGTD/EE group had a significantly shorter length of bleeding episodes (4 vs. 5 days, p < 0.001), a significantly lower intensity of bleeding (p < 0.01) and a significantly shorter time for onset of withdrawal bleeding than the DSG/EE group (p < 0.001). Safety profiles for the two treatment groups were similar. Significantly more subjects in the DSG/ EE group withdrew because of breast pain (p =0.03) and nausea or vomiting (p = 0.05). One pregnancy occurred in each treatment group. CONCLUSIONS: The 24-day regimen of GTD 60 microg/EE 15 microg provided good efficacy, acceptable cycle control and a favorable safety profile compared with DSG/EE. This ultra-low-dose formulation offers unique advantages in efficacy and safety for oral contraception

Journals Database
MeSH Database
SingleCitation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries

Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
[pic]
|[pic]1: Eur J Contracept Reprod Health Care. 1999 Nov;4 |
|Suppl 2:9-15. |

The safety and contraceptive efficacy of a 24-day low-doseoral contraceptive regimen containing gestodene 60 microg and ethinylestradiol 15 microg.

[No authors listed]

OBJECTIVE: The safety and contraceptive efficacy of a new 24-day regimen of an oral contraceptive combination containing gestodene (GTD) 60 microg and ethinylestradiol (EE) 15 microg was evaluated in an open-label, multicenter study. METHODS: Adult women received GTD 60microg/EE 15 microg from day 1 to 24 and 4 days of placebo during a 28-day cycle for either 13 or 19 cycles. RESULTS: Of the 1515 subjects enrolled, 1496 were included in the intent-to-treat analysis. A total of three pregnancies were reported during the 18 194 treatment cycles of the study, yielding a Pearl index of 0.21. Life-table analysis, based on 16 954 cycles, gave an accidental pregnancyrate of 0.0033. The most frequent adverse events were headache (reported in 35% of subjects), absence of bleeding (16%), flu-like syndrome (15%), pharyngitis (15%) and abdominal pain (15%). The most frequent reasons for withdrawal from the study were metrorrhagia, flu syndrome and absence of bleeding. Analyses of withdrawal and intermenstrual bleeding and spotting indicated acceptable cycle control.CONCLUSIONS: The 24-day GTD 60 microg/EE 15 microg regimen appears to be a well-tolerated and effective method for low-dose oral contraception. The current formulation offers an ultra-low steroidal dosage combined with a reduced pill-free interval to improve contraceptive efficacy

|Contraception. 1999 Sep;60(3):151-4. |

 
Endometrial histology during use of a low-dose...
tracking img